DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness

Phase 3

Completed

Conditions: Venous Thrombosis
Pulmonary Embolism

Interventions: Drug: Apixaban
Drug: Enoxaparin

First Posted Date: 2007-04-05

Last Posted Date: 2015-12-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6758

Registration Number: NCT00457002

Locations: 🇺🇸
Pulmonary & Critical Care Of Atlanta, Atlanta, Georgia, United States
🇺🇸
Atlanta Institute For Medical Research, Inc, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States

and more 45 locations

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Doxorubicin

First Posted Date: 2007-04-03

Last Posted Date: 2016-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 384

Registration Number: NCT00455533

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Florida Cancer Research Institute, Davie, Florida, United States
🇺🇸
Albert Einstein Cancer Center, Bronx, New York, United States

and more 8 locations

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

Phase 2

Completed

Conditions: Disorder Related to Renal Transplantation

Interventions: Drug: Thymoglobulin
Drug: Tacrolimus
Drug: Belatacept
Drug: Mycophenolate Mofetil (MMF)
Drug: Sirolimus

First Posted Date: 2007-04-02

Last Posted Date: 2014-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 93

Registration Number: NCT00455013

Locations: 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸
Denver Nephrology, Pc, Denver, Colorado, United States
🇺🇸
University Of Colorado Health Sciences Center, Denver, Colorado, United States

and more 9 locations

Expanded Access for Dasatinib

First Posted Date: 2007-04-02

Last Posted Date: 2022-04-29

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00454753

Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer

Phase 1

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: Dasatinib
Drug: Capecitabine

First Posted Date: 2007-03-27

Last Posted Date: 2015-03-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 52

Registration Number: NCT00452673

Locations: 🇪🇸
Local Institution, Sevilla, Spain
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
City Of Hope National Medical Center, Duarte, California, United States

and more 2 locations

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery

Phase 3

Completed

Conditions: Pulmonary Embolism
Deep Vein Thrombosis

Interventions: Drug: Apixaban
Drug: Enoxaparin
Drug: Apixaban-matching placebo
Drug: Enoxaparin-matching placebo

First Posted Date: 2007-03-27

Last Posted Date: 2014-07-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3221

Registration Number: NCT00452530

Locations: 🇬🇧
Local Institution, Epsom, Surrey, United Kingdom

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Colorectal Cancer
Prostate Cancer
Renal Cancer
Malignant Melanoma

Interventions: Biological: MDX-1106

First Posted Date: 2007-02-28

Last Posted Date: 2015-02-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT00441337

Locations: 🇺🇸
Washington University School of Medicine - Barnes Jewish Hospital, St. Louis, Missouri, United States
🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸
Carolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States

and more 1 locations

Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Prostate Cancer

Interventions: Drug: Dasatinib
Drug: Docetaxel

First Posted Date: 2007-02-23

Last Posted Date: 2014-03-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 49

Registration Number: NCT00439270

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Hematology-Oncology Associates Of Rockland, Nyack, New York, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 2 locations

A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: Brivanib

First Posted Date: 2007-02-21

Last Posted Date: 2013-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 29

Registration Number: NCT00437437

Locations: 🇺🇸
Dana-Farber Harvard Cancer Care, Boston, Massachusetts, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸
Duke University Medical Center-Dept Of Medicine, Durham, North Carolina, United States

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Phase 1

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Brivanib

First Posted Date: 2007-02-21

Last Posted Date: 2011-05-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT00437424

Locations: 🇪🇸
Local Institution, Sevilla, Spain
🇺🇸
University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy